| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
21.07.2025 07:33:25
|
Roche Announces Mixed Results For Astegolimab In COPD Trials
(RTTNews) - Roche (RHHBY) announced results from two clinical trials evaluating astegolimab in people with moderate to very severe chronic obstructive pulmonary disease or COPD, alongside standard maintenance therapy.
The pivotal Phase IIb ALIENTO trial met its primary endpoint, showing a statistically significant 15.4% reduction in annualized exacerbation rate (AER) at 52 weeks, with dosing every two weeks.
In contrast, the Phase III ARNASA trial did not meet its primary endpoint, recording a numerical AER reduction of 14.5% at 52 weeks, which did not reach statistical significance.
The company noted that results across secondary endpoints were generally consistent in both studies. The overall number of exacerbations was lower than anticipated. Astegolimab's safety profile aligned with previously reported data, with no new safety signals identified.
For More Such Health News, visit rttnews.com.
Nachrichten zu Roche Holding AG Sponsored American Deposit Receipt Repr 1/2 NVTGSh
|
24.07.25 |
Roche erwägt Direktverkauf von Medikamenten an US-Patienten (Dow Jones) | |
|
23.06.25 |
Roche-Aktie fester: Roche zeigt Erfolge bei Krebs- und Hämophilie-Therapien (finanzen.ch) | |
|
11.06.25 |
Roche-CEO: Trumps Arznei-Preis-Dekret bedroht US-Investitionen (Dow Jones) | |
|
23.05.25 |
Roche-Aktie: Roche erhält FDA-Zulassung für Augentherapie Susvimo (Dow Jones) | |
|
03.04.25 |
Roche-Aktie schwächelt: Roche treibt Krebsdiagnostik voran - Forschungsrückschlag mit Ocrevus (finanzen.ch) | |
|
05.02.25 |
Roche punktet bei der FDA: Grünes Licht für Susvimo gegen diabetesbedingte Erblindung - Aktie in Grün (Dow Jones) |